SciFi Futures
← Capabilities
Biotech & Medicine/Integrated system

Gene-edited xenograft donor animals

Herds of genetically modified pigs, raised in designated-pathogen-free facilities, whose organs can be transplanted into humans.

State of the art

United Therapeutics 10-edit UKidney began the EXPAND trial at NYU Langone (November 2025); eGenesis 69-edit EGEN-2784 got IND clearance (September 2025); best expanded-access graft survival to date is 271 days, and a pig liver supported a patient for 171 days.

What’s blocking it
  • Graft survival measured in months, not years - chronic rejection and thrombotic microangiopathy persist
  • Porcine endogenous retrovirus and novel-zoonosis risk requires lifelong recipient surveillance
  • Organ growth mismatch and porcine protein incompatibilities (complement, coagulation) are only partly corrected by current edit sets
  • Designated-pathogen-free breeding and organ-recovery facilities do not exist at transplant-program scale

Who’s working on it

  • Its 10-edit UKidney entered the EXPAND trial at NYU Langone in November 2025; it is building designated-pathogen-free herds, including a $110M facility in Stewartville, Minnesota due to operate in 2027, toward thousands of organs a year

  • Got FDA IND clearance for the 69-edit EGEN-2784 kidney in September 2025; its expanded-access recipient passed seven months dialysis-free, the longest survival with an engineered porcine organ

  • David AyaresResearcher
    Revivicor, United Therapeutics

    Made the original alpha-gal knockout pigs and the multi-edit donor lines used in nearly every US xenotransplant to date

  • Robert MontgomeryResearcher
    NYU Langone Transplant Institute

    Performed the first decedent xenokidney transplants (2021) and led the first transplant in the EXPAND clinical trial (November 2025)

  • Tatsuo KawaiResearcher
    Massachusetts General Hospital

    Lead transplant surgeon for the eGenesis kidney recipients (2025) and director of MGH's clinical transplant tolerance centre

  • Chengdu Zhongke Aoge (Clonorgan)Company

    Chinese producer of gene-edited donor pigs aiming at mass supply for domestic hospitals, the main effort outside the US

What to invest in

KindInvestmentScale
infrastructureDesignated-pathogen-free breeding and organ-recovery facilities sized for thousands of transplants per year$$$ $100M – $1B
researchHead-to-head trials resolving how many edits a durable xenograft actually needs, with multi-year follow-up$$$ $100M – $1B

Sci-fi concepts in reach

Engineered organ-donor animalsdirectCyborg body augmentationdirect

Sources